Inhibrx Inc INBX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 2:19 PM EST
25.55quote price arrow down-1.25 (-4.66%)
Volume
201,862
52 week range
15.20 - 50.97

...

Loading . . .

KEY STATS

  • Open27.42
  • Day High27.99
  • Day Low24.69
  • Prev Close26.80
  • 52 Week High50.97
  • 52 Week High Date12/18/20
  • 52 Week Low15.20
  • 52 Week Low Date11/02/20
  • Market Cap963.49M
  • Shares Out37.71M
  • 10 Day Average Volume0.43M
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-1.44
  • P/E (TTM)-17.72
  • Fwd P/E (NTM)-11.55
  • EBITDA (MRQ)-60.254M
  • ROE (MRQ)-
  • Revenue (MRQ)5.69M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-1,307.68%
  • Debt To Equity (MRQ)12.75%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Inhibrx Inc News

There is no recent news for this security.

Latest INBX News From Our Partners

February 16, 2021

February 14, 2021

QUOTE FINDER

Profile

MORE
Inhibrx Inc. is a clinical-stage biotechnology company. The Company is focused on developing biologic therapeutics for people with life-threatening conditions. It has a pipeline of novel biologic therapeutic candidates, developed using its single domain antibody (sdAb) platform. Its pipeline includes INBRX-109, INBRX-106, INBRX-105 and INBRX-101. INBRX-109 is a tetravalent death receptor 5 (DR5) agonist being evaluated in patients diagnosed with chondrosarcoma and...
Mark Lappe
Chairman
Kelly Deck
Chief Financial Officer
Klaus Wagner M.D., Ph.D.
Executive Vice President
Address
11025 N. Torrey Pines Road
Suite 200, La Jolla
La Jolla, CA
92037
United States